# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k173195   
B. Purpose for Submission: Adding a previously cleared test (DRI Hydrocodone Assay) to the Indiko   
C. Measurand: Hydrocodone   
D. Type of Test: Qualitative and semi-quantitative homogeneous enzyme immunoassay   
E. Applicant: Microgenics Corporation   
F. Proprietary and Established Names: DRI Hydrocodone Assay

# G. Regulatory Information:

1. Regulation section: 21 CFR 862.3650, Opiate test system

2. Classification: Class II

3. Product code: DJG

4. Panel: Toxicology (91)

# H. Intended Use:

1. Intended use(s): Refer to Indications for Use below

2. Indication(s) for use:

The DRI Hydrocodone Assay is a homogeneous enzyme immunoassay for the qualitative and/or semi-quantitative determination of the presence of hydrocodone and its metabolites in human urine at a cutoff concentration of $3 0 0 ~ \mathrm { { n g / m L } }$ . The assay is intended to be used in laboratories and provides a simple and rapid analytical screening procedure to detect hydrocodone and its metabolites in human urine. The assay is designed for use with a number of clinical chemistry analyzers.

The semi-quantitative mode is for the purpose of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as liquid chromatography/tandem mass spectrometry (LC-MS/MS) or permitting laboratories to establish quality control procedures. The assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/ mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC-MS/MS) is the preferred confirmatory method.

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements:

Performance characteristics provided in this submission were determined on the Indiko Plus Analyzer.

# I. Device Description:

The DRI Hydrocodone assay is supplied as a liquid ready-to-use homogeneous enzyme immunoassay, comprised of two reagents (Reagent A and Reagent E) which are bottled separately but sold together within the same kit.

Reagent A: Contains mouse monoclonal anti-Hydrocodone antibody, glucose-6-phosphate (G6P), and nicotinamide adenine dinucleotide (NAD) in Tris buffer with sodium azide as a preservative.

Reagent E: Contains Hydrocodone derivative labeled with glucose-6-phosphate dehydrogenase (G6PDH) in Tris buffer with sodium azide as a preservative.

# J. Substantial Equivalence Information:

1. Predicate device name(s): DRI Hydrocodone assay

2. Predicate 510(k) number(s): k150502

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities and Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Candidate Devicek173195</td><td rowspan=1 colspan=1>Predicate Devicek150502</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Homogeneous enzymeimmunoassay forthe qualitative and/orsemi-quantitativedetermination of thepresence of hydrocodoneand its metabolites inhuman urine.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measured Analyte</td><td rowspan=1 colspan=1>Hydrocodone and itsmetabolites</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Test Matrix</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cutoff Levels</td><td rowspan=1 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Homogeneous EnzymeImmunoassay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Mouse Monoclonal</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>28°C until expirationdate</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>Indiko Plus</td><td rowspan=1 colspan=1>Beckman AU680</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP5-A3: Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline -Third Edition, 2014. CLSI EP7-A2: Interference Testing in Clinical Chemistry; Approved Guideline -Second Edition, 2005. · CLSI EP9-A3: Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline -Third Edition, 2013. CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures, a Statistical Approach; Approved Guideline, 2003.

· CLSI EP25-A: Evaluation of Stability ofTn Vitro Diagnostic Reagents; Approved Guideline, 2009.

# L. Test Principle:

The DRI Hydrocodone Assay is a homogeneous enzyme immunoassay. The assay uses specific antibodies that can detect Hydrocodone and its metabolites. The assay is based on competition between a drug labeled with glucose-6-phosphate dehydrogenase (G6PDH) and free drug from the urine sample, for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, mouse monoclonal anti-hydrocodone antibody binds to the drug labeled with G6PDH and causes a decrease in enzyme activity. In the presence of free drug, the free drug occupies the antibody binding sites, allowing the drug bound G6PDH to interact with the substrate, resulting in enzyme activity. This phenomenon creates a direct proportional relationship between the drug concentration in urine and enzyme activity. The enzyme activity is determined spectrophotometrically at $3 4 0 \mathrm { n m }$ by measuring the conversion of nicotinamide adenine dinucleotide (NAD) to NADH.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

A precision study was performed following CLSI EP5‐A3. Drug free urine samples were spiked with hydrocodone at 0, 75, 150, 225, 300, 375, 450, 525 and $6 0 0 ~ \mathrm { { n g / m L } }$ , representing 0, 25, 50, 75, 100, 125, 150, 175 and $20 \%$ of the device cutoff $( 3 0 0 ~ \mathrm { n g / m L } )$ . Each level sample was tested in duplicate per run, two runs per day for twenty consecutive days (total $\mathrm { n } { = } 8 0 ,$ /level/reagent lot) using 2 lots on one Indiko Plus analyzer in both qualitative and semiquantitative modes. The results of one representative lot are shown below:

Qualitative Precision Result:   

<table><tr><td colspan="1" rowspan="1">Concentration as% of the CutoffLevel</td><td colspan="1" rowspan="1">TargetHydrocodonespikedconcentration(ng/mL)</td><td colspan="1" rowspan="1">Hydrocodoneconcentrationdeterminedby LC-MS/MS(ng/mL)</td><td colspan="1" rowspan="1">DRI HydrocodoneAssay# Negative / # Positive</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">80 Neg/ 0 Pos</td></tr><tr><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">89.5</td><td colspan="1" rowspan="1">80 Neg/0 Pos</td></tr><tr><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">174.85</td><td colspan="1" rowspan="1">80 Neg/0 Pos</td></tr><tr><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">225</td><td colspan="1" rowspan="1">243.37</td><td colspan="1" rowspan="1">80 Neg/ 0 Pos</td></tr><tr><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">318.50</td><td colspan="1" rowspan="1">4 Neg/76 Pos</td></tr><tr><td colspan="1" rowspan="1">125</td><td colspan="1" rowspan="1">375</td><td colspan="1" rowspan="1">410.66</td><td colspan="1" rowspan="1">0 Neg/80 Pos</td></tr><tr><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">450</td><td colspan="1" rowspan="1">501.62</td><td colspan="1" rowspan="1">0 Neg80 Pos</td></tr><tr><td colspan="1" rowspan="1">175</td><td colspan="1" rowspan="1">525</td><td colspan="1" rowspan="1">592.11</td><td colspan="1" rowspan="1">0 Neg80 Pos</td></tr><tr><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">600</td><td colspan="1" rowspan="1">667.52</td><td colspan="1" rowspan="1">0 Neg80 Pos</td></tr><tr><td colspan="1" rowspan="1">Concentrationas % of theCutoff Level</td><td colspan="1" rowspan="1">TargetHydrocodonespikedconcentration(ng/mL)</td><td colspan="1" rowspan="1">Hydrocodoneconcentrationdeterminedby LC-MS/MS(ng/mL)</td><td colspan="1" rowspan="1">DRI HydrocodoneAssay# Negative / # Positive</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">80 Neg/ 0 Pos</td></tr><tr><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">89.5</td><td colspan="1" rowspan="1">80 Neg0 Pos</td></tr><tr><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">174.85</td><td colspan="1" rowspan="1">80 Neg0 Pos</td></tr><tr><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">225</td><td colspan="1" rowspan="1">243.37</td><td colspan="1" rowspan="1">80 Neg0 Pos</td></tr><tr><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">318.50</td><td colspan="1" rowspan="1">7 Neg / 73 Pos</td></tr><tr><td colspan="1" rowspan="1">125</td><td colspan="1" rowspan="1">375</td><td colspan="1" rowspan="1">410.66</td><td colspan="1" rowspan="1">0 Neg80 Pos</td></tr><tr><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">450</td><td colspan="1" rowspan="1">501.62</td><td colspan="1" rowspan="1">0 Neg80 Pos</td></tr><tr><td colspan="1" rowspan="1">175</td><td colspan="1" rowspan="1">525</td><td colspan="1" rowspan="1">592.11</td><td colspan="1" rowspan="1">0 Neg80 Pos</td></tr><tr><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">600</td><td colspan="1" rowspan="1">667.52</td><td colspan="1" rowspan="1">0 Neg80 Pos</td></tr></table>

# b. Linearity/assay reportable range:

A drug recovery study in the semi-quantitative mode was conducted by spiking a drug free urine pool with hydrocodone and using serial dilutions with a negative urine pool to achieve concentrations ranging from $1 0 0 ~ \mathrm { { n g / m L } }$ to $1 0 0 0 \mathrm { { n g / m L } }$ , and testing each level on one lot of reagent, calibrators and controls. Each concentration was tested in five replicates on the Indiko Plus analyzer. The mean of the five replicates tested was defined as the observed drug concentration value. The percent recovery range was defined as the range in observed percent recoveries amongst the five replicates at each concentration. The results of are summarized below:

<table><tr><td rowspan=1 colspan=1>Targetconcentration(ng/mL)</td><td rowspan=1 colspan=1>Observedconcentration(ng/mL)</td><td rowspan=1 colspan=1>% RecoveryRange</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>80-120</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>160-240</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>331</td><td rowspan=1 colspan=1>240-360</td></tr><tr><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>427</td><td rowspan=1 colspan=1>320-480</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>529</td><td rowspan=1 colspan=1>400-600</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>624</td><td rowspan=1 colspan=1>480-720</td></tr><tr><td rowspan=1 colspan=1>700</td><td rowspan=1 colspan=1>696</td><td rowspan=1 colspan=1>560-840</td></tr><tr><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>798</td><td rowspan=1 colspan=1>640-960</td></tr><tr><td rowspan=1 colspan=1>900</td><td rowspan=1 colspan=1>893</td><td rowspan=1 colspan=1>720-1080</td></tr><tr><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>911</td><td rowspan=1 colspan=1>800-1200</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Calibrators for this device were previously cleared in k150502.

d. Detection limit:

Not applicable.

e. Analytical specificity:

An analytical specificity study to evaluate interference from non-structurally and structurally related compounds was performed in the qualitative and semi-quantitative modes. The study design and results were the same for each mode (qualitative and semi-quantitative modes) and are shown in the tables below.

Cross-Reactivity of Hydrocodone and Its Metabolites

To evaluate potential cross-reactivity for the DRI Hydrocodone assay, structurally similar compounds were spiked into drug free urine at concentrations that will yield a result that is equivalent to the $3 0 0 \mathrm { n g / m L }$ cutoff. Percent cross-reactivity for compounds with no observed cross-reactivity was calculated using the highest concentration tested. The percent cross-reactivity is presented in the table below.

Cross-Reactivity of Opiates and Structurally Related Compounds   

<table><tr><td rowspan=1 colspan=1>Hydrocodone and its metabolites</td><td rowspan=1 colspan=1>TestedConcentration(ng/mL)</td><td rowspan=1 colspan=1>Pos/neg</td><td rowspan=1 colspan=1>% Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Hydrocodone</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone</td><td rowspan=1 colspan=1>325</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>92</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone-3β-glucuronide</td><td rowspan=1 colspan=1>185</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>162</td></tr><tr><td rowspan=1 colspan=1>Norhydrocodone</td><td rowspan=1 colspan=1>13,000</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Dihydrocodeine</td><td rowspan=1 colspan=1>12,500</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>2</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Compounds</td><td colspan="1" rowspan="1">TestedConcentration(ng/mL)</td><td colspan="1" rowspan="1">% Cross-Reactivity</td></tr><tr><td colspan="1" rowspan="1">6 -Acetyl Morphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">&lt; 0.3</td></tr><tr><td colspan="1" rowspan="1">Buprenorphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">&lt; 0.3</td></tr><tr><td colspan="1" rowspan="1">Buprenorphine 3β-D -Glucuronide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">&lt; 0.3</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">150,000</td><td colspan="1" rowspan="1">&lt; 0.2</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">250,000</td><td colspan="1" rowspan="1">&lt; 0.2</td></tr><tr><td colspan="1" rowspan="1">EDDP</td><td colspan="1" rowspan="1">150,000</td><td colspan="1" rowspan="1">&lt; 0.2</td></tr><tr><td colspan="1" rowspan="1">Fentanyl</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">&lt; 0.3</td></tr><tr><td colspan="1" rowspan="1">Heroin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">&lt; 0.3</td></tr><tr><td colspan="1" rowspan="1">Levorphanol</td><td colspan="1" rowspan="1">22,000</td><td colspan="1" rowspan="1">1.7</td></tr><tr><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">&lt;0.3</td></tr><tr><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">&lt;0.3</td></tr><tr><td colspan="1" rowspan="1">Morphine</td><td colspan="1" rowspan="1">150,000</td><td colspan="1" rowspan="1">&lt;0.2</td></tr><tr><td colspan="1" rowspan="1">Morphine -3β-D-Glucuronide</td><td colspan="1" rowspan="1">70,000</td><td colspan="1" rowspan="1">&lt;0.4</td></tr><tr><td colspan="1" rowspan="1">Morphine -6 β-D-Glucuronide</td><td colspan="1" rowspan="1">75,000</td><td colspan="1" rowspan="1">&lt;0.4</td></tr><tr><td colspan="1" rowspan="1">Nalbuphine</td><td colspan="1" rowspan="1">150,000</td><td colspan="1" rowspan="1">&lt;0.3</td></tr><tr><td colspan="1" rowspan="1">Naloxone</td><td colspan="1" rowspan="1">17,000</td><td colspan="1" rowspan="1">2.0</td></tr><tr><td colspan="1" rowspan="1">Naltrexone</td><td colspan="1" rowspan="1">75,000</td><td colspan="1" rowspan="1">&lt;0.3</td></tr><tr><td colspan="1" rowspan="1">Norbuprenorphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">&lt;0.3</td></tr><tr><td colspan="1" rowspan="1">Norcodeine</td><td colspan="1" rowspan="1">150,000</td><td colspan="1" rowspan="1">&lt;0.2</td></tr><tr><td colspan="1" rowspan="1">Normorphine</td><td colspan="1" rowspan="1">150,000</td><td colspan="1" rowspan="1">&lt;0.2</td></tr><tr><td colspan="1" rowspan="1">Nor-Oxycodone</td><td colspan="1" rowspan="1">110,000</td><td colspan="1" rowspan="1">0.3</td></tr><tr><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">14,000</td><td colspan="1" rowspan="1">2.5</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone 6β-D- Glucuronide</td><td colspan="1" rowspan="1">14,000</td><td colspan="1" rowspan="1">2.2</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone</td><td colspan="1" rowspan="1">14,000</td><td colspan="1" rowspan="1">2.5</td></tr><tr><td colspan="1" rowspan="1">Tapentadol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">&lt;0.3</td></tr><tr><td colspan="1" rowspan="1">Thebaine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">&lt;0.3</td></tr><tr><td colspan="1" rowspan="1">Tramadol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">&lt;0.3</td></tr></table>

# Structurally Unrelated Compounds

Potential interference from non-structurally related drugs was evaluated in the qualitative and semi-quantitative modes, by spiking these compounds at high concentrations in drug free urine spiked with hydrocodone at $\pm 2 5 \%$ of the cutoff (225 and $3 7 5 ~ \mathrm { { n g / m L } }$ ). Results obtained with two reagent lots were the same, and results from one representative lot are provided in the table below.

<table><tr><td colspan="1" rowspan="2">Compounds</td><td colspan="1" rowspan="2">Spiked Concentration(ng/mL)</td><td colspan="2" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">+25%Cutoff (375ng/mL)</td><td></td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic acid</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Amitryptyline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Amphetamine</td><td colspan="1" rowspan="1">1,000,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">1,000,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">10,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Cimitidine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Desipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Doxepine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ephedrine</td><td colspan="1" rowspan="1">1,000,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Fluoxethine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Fluphenazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Maprotiline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Nortryptiline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">250,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Phencyclidine (PCP)</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ranitidine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Secobarbital</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Thioridazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr></table>

# Endogenous Compounds, pH and Specific Gravity

Potentially interfering substances were spiked into drug free urine spiked with 225 $\mathrm { { n g / m L } }$ or $3 7 5 ~ \mathrm { { n g / m L } }$ of hydrocodone. Samples were tested in replicates of five $( \mathrm { n } { = } 5 )$ in both qualitative and semi-quantitative modes. Results obtained in both modes were identical, and results are provided in the below table.

<table><tr><td rowspan=1 colspan=1>Potential InterferingSubstances</td><td rowspan=1 colspan=1>Concentrationtested (mg/dL)</td><td rowspan=1 colspan=1>-25% Cutoff(225ng/mL)</td><td rowspan=1 colspan=1>+25% Cutoff(375ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Acetylsalycylic Acid</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Galactose</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>1,000</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Human Serum Albumin (HSA)</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Oxalic acid</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Riboflavin</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Sodium Chloride</td><td rowspan=1 colspan=1>1,000</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>1,000</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr></table>

pH: Drug free urine specimens spiked with 225 or $3 7 5 ~ \mathrm { { n g / m L } }$ of hydrocodone were adjusted to varying $\mathsf { p H }$ (between $\mathsf { p H 4 . 0 }$ and $\mathrm { p H } 1 0 . 0 )$ . Samples were tested in replicates of five $( \mathrm { n } { = } 5 )$ in both qualitative and semi-quantitative modes. No positive or negative interference was observed at urine $\mathrm { p H }$ values ranging from 4.0 to 10.0 for each test mode.

Specific Gravity: Urine with specific gravity spanning the range within 1.003–1.031 was spiked with 225 and $3 7 5 ~ \mathrm { { n g / m L } }$ of hydrocodone. Samples were tested in replicates of five $( \mathrm { n } { = } 5 )$ in both qualitative and semi-quantitative. No positive or negative interference was observed at urine specific gravity values ranging from 1.003 to 1.031 in either test mode.

Assay cut-off:

Characterization of how the device performs analytically around the claimed cutoff concentration of $3 0 0 ~ \mathrm { { n g / m L } }$ hydrocodone is described in the precision section, M.1.a. above.

2. Comparison studies:

# a. Method comparison with predicate device:

A total of 136 unaltered urine samples were analyzed by one lot of the DRI Hydrocodone Assay in one replicate, in both Qualitative and Semi-quantitative modes, and the results were compared to LC-MS/MS (liquid- chromatographytandem mass spectroscopy). The results from the study in the two modes were identical and are summarized in the table below.

<table><tr><td>Candidate Device Results</td><td>Negative</td><td>&lt;50% of cutoff concentration by LC/MS (&lt; 150ng/mL)</td><td>Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration by LC/MS) (150 ~ 299</td><td>Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration by LC/MS) (300 ~ 450</td><td>High Positive (Greater than 50% above the cutoff concentration by LC/MS) &gt; 450 ng/mL</td></tr><tr><td>Positive</td><td></td><td></td><td>ng/mL) 17*</td><td>ng/mL) 9</td><td>48</td></tr><tr><td>Negative</td><td>0 42</td><td>7* 3</td><td>10</td><td>0</td><td>0</td></tr></table>

<table><tr><td rowspan=3 colspan=1>Sample #</td><td rowspan=3 colspan=1>Immunoassayresult</td></tr><tr><td rowspan=1 colspan=2>LC-MS/MS (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Hydrocodone</td><td rowspan=1 colspan=1>Hydromorphone3β-DGlucuronide</td></tr><tr><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>179</td></tr><tr><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>160</td></tr><tr><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>314</td></tr><tr><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>82.7</td><td rowspan=1 colspan=1>128</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>138</td><td rowspan=1 colspan=1>677</td></tr><tr><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>126</td></tr><tr><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>73.3</td><td rowspan=1 colspan=1>262</td></tr><tr><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>218</td></tr><tr><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>249</td><td rowspan=1 colspan=1>356</td></tr><tr><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>253</td><td rowspan=1 colspan=1>265</td></tr><tr><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>739</td></tr><tr><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>88.6</td></tr><tr><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>217</td><td rowspan=1 colspan=1>158</td></tr><tr><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>236</td><td rowspan=1 colspan=1>90.4</td></tr><tr><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>282</td><td rowspan=1 colspan=1>242</td></tr><tr><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>295</td><td rowspan=1 colspan=1>433</td></tr><tr><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>167</td><td rowspan=1 colspan=1>149</td></tr><tr><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>193</td><td rowspan=1 colspan=1>756</td></tr><tr><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>214</td><td rowspan=1 colspan=1>434</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>207</td><td rowspan=1 colspan=1>706</td></tr><tr><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>298</td><td rowspan=1 colspan=1>190</td></tr><tr><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>198</td><td rowspan=1 colspan=1>262</td></tr><tr><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>124</td></tr><tr><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>287</td><td rowspan=1 colspan=1>79.9</td></tr></table>

$b$ . Matrix comparison: Not applicable. Urine is the only claimed matrix for the candidate device.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.

b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Not applicable.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.